breast cancer index

Release time ：Dec-21,2024

The Breast Cancer Index (BCI) is a biomarker that evaluates the risk of recurrence and responsiveness to endocrine therapy in breast cancer patients. It is typically determined by measuring specific protein levels in the blood. The BCI assists physicians in devising more personalized treatment plans and in forecasting patient outcomes.

The normal range for the BCI can vary based on factors such as age, gender, and the type of breast cancer. Generally, a BCI value below the normal range might suggest a lower risk of recurrence and a more favorable response to treatment for the patient. However, this does not imply that further treatment is unnecessary. Instead, physicians may develop treatment strategies based on the patient's unique circumstances and additional biomarker results.

Regular monitoring of the BCI is crucial for breast cancer patients. An abnormally high BCI could indicate a deterioration in the patient's condition or a suboptimal response to therapy. In such instances, physicians might revise the treatment plan or implement alternative measures to manage the disease. Concurrently, patients are advised to adhere to their doctors' recommendations and maintain healthy lifestyle practices, including a balanced diet, regular exercise, and abstaining from smoking and limiting alcohol consumption, to enhance the efficacy of treatment and overall quality of life.